
Endo Pharmaceuticals, the Malvern-based drugmaker, has agreed to pay around $658 million for BioSpecifics Technologies, a 20-year-old Wilmington company whose collagen-based injection treatments were approved by the Food and Drug Administration earlier this year to fight “moderate to severe cellulite in the buttocks of adult women.” Endo plans to market the treatment under the brand… Read more »